Date: 2013-09-23
Type of information: Production agreement
Compound: TMX-302
Company: Telormedix (Switzerland) Molecular Profiles (UK), a subsidiary of Columbia Laboratories (USA)
Therapeutic area: Autoimmune diseases – Dermatological diseases
Type agreement: development
manufacturing
production
Action mechanism: TMX-302 belongs to a novel class of small molecule developed by Telormedix acting as Toll-like receptor 7 (TLR7) “weak agonists” to potently dampen the inflammatory response without inducing immunosuppression, thus potentially fulfilling the above requirements. In in vivo studies, these compounds have been shown to be well tolerated upon systemic administration and to exert a potent anti-inflammatory activity without inducing a state of immunosuppression. These TLR7 weak agonists hold the promise of generating improved anti-inflammatory responses in the treatment of psoriasis.
Disease: psoriasis
Details: * On September 23, 2013, Molecular Profiles, a subsidiary of Columbia Laboratories, has announced that it has been selected as the formulation development partner for a major pan-European collaborative project. The UK-based company has been chosen by clinical stage biopharmaceutical company Telormedix to develop both topical and solid dosage formulations for the use in the treatment of psoriasis. The project, operating under the acronym PAT (Psoriasis Anti-inflammatory Treatment), will involve other consortium partners Biopta, Midatech Biogune and the University Hospital Zurich. Telormedix raised funding from the European Eurostars Programme to coordinate this international research project for TMX-302, which will use Midatech’s glycan-coated gold nanoparticles formulated using Molecular Profiles’ expertise.
The deal comes just weeks after Molecular Profiles announced the official opening of its new facility following a successful inspection from the Medical and Healthcare products Regulatory Agency (MHRA), and on the heels of its acquisition by Columbia Laboratories, a Boston-based company with a rich heritage in drug development.
Financial terms:
Latest news:
